Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer

Yungang Wang,1 Yanxia Ding,2 Yijun Deng,3 Yu Zheng,1 Shengjun Wang

ABSTRACT
Colitis-associated cancer (CAC) is a specific type of colorectal cancer that develops from inflammatory bowel disease (IBD). Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that are essential for the pathological processes of inflammation and cancer. Accumulating evidence indicates that MDSCs play different but vital roles during IBD and CAC development and impede CAC immunotherapy. New insights into the regulatory network of MDSCs in the CAC pathogenesis are opening new avenues for developing potential CAC therapeutic strategies based on MDSC blockade.

INTRODUCTION
Colitis-associated cancer (CAC) follows the sequence of normal tissue, hyperplasia, high-grade dysplasia, and adenocarcinoma. The etiology of CAC includes epigenetic changes, somatic mutations, and chronic inflammation. Inflammatory bowel disease (IBD), which is composed of Crohn’s disease (CD) and ulcerative colitis (UC), is the result of continuous microbial antigen-induced immune responses as a consequence of host genetic defects in intestinal mucosal barrier function, immunomodulation, or bacterial killing. IBD is a high-risk factor for CAC. A meta-analysis of 54,478 patients with UC, including 1,698 cases of CAC, found that the overall prevalence of colorectal cancer (CRC) among UC cases was 3.7%. The cumulative risk for CAC in patients with CD has been reported to be 18.4% after 30 years of disease duration. On the one hand, inflammation causes strong genotoxic reactions, such as DNA damage and mutations in important genes, which subsequently drive CAC initiation. On the other hand, inflammation activates the Wnt/β-catenin signaling pathway, which induces intestinal epithelial cell (IEC) proliferation and remodeling and then promotes CAC development. CAC provides a great model to understand the role of chronic inflammation in tumors. However, the exact cause of chronic inflammation in patients with IBD and the key driver of the conversion from IBD to CAC still remain unknown.

The massive infiltration of myeloid cells and lymphocytes into the inflamed intestinal tissue is the main pathological feature of IBD. Dendritic cells (DCs) and macrophages sense invading micro-organisms and regulate the differentiation of proinflammatory lymphocytes such as T helper (Th1) cells, Th17 cells, innate lymphoid cells (ILCs), and interleukin (IL)-17+ γδT cells. The lymphocytes further recruit myeloid cells into the local intestinal tissue. These myeloid cells play an important role in promoting the conversion of IBD to CAC. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid progenitors and immature myeloid cells. In IBD and CAC, MDSCs massively infiltrate the inflamed intestinal tissue and tumor microenvironment and have been a research focus due to their roles in inflammation and tumorigenesis. Currently, the functional and phenotypic heterogeneity of MDSCs leads to controversy about their role in IBD. Furthermore, the mechanism by which MDSCs regulate the conversion from IBD to CAC is largely unknown. This review mainly focuses on the identification of MDSCs in patients with IBD or CAC, emerging insights into the regulatory network of MDSCs in IBD and CAC pathogenesis, and new possible avenues for CAC immunotherapy by targeting MDSCs.

IDENTIFICATION OF MDSCS IN IBD/CAC
MDSCs mainly include granulocytic and monocytic subsets. The identification of MDSC subsets in CAC is still difficult, which
is mainly attributed to the diverse origins, heterogeneous phenotypes, and mutual transformation of myeloid cells.

**Identification of colorectal-infiltrating MDSCs**

The morphology and phenotype of granulocytic MDSCs (G-MDSCs or polymorphonuclear (PMN)-MDSCs) and monocytic MDSCs (M-MDSCs) are similar to those of neutrophils and monocytes, respectively. Murine MDSCs are defined as Gr-1⁺CD11b⁺ cells. G-MDSCs and M-MDSCs are defined as CD11b⁺Ly6G⁻Ly6C⁰ cells and CD11b⁺Ly6G⁺Ly6C² cells, respectively. Human MDSCs are extensively described as HLA-DR⁺CD11b⁺CD3³⁺ cells. G-MDSCs and M-MDSCs are described as HLA-DR⁺CD11b⁺CD3³⁺CD15⁻ cells and HLA-DR⁺CD11b⁺CD3³⁺CD14⁻ cells, respectively. Intestine-infiltrating MDSCs were first described as CD11b⁺Gr-1⁺ cells with immunosuppressive functions.
in CD8+ T cell-mediated colitis mice.4 Later, colonic G-MDSCs were described as Mac-1Ly6C+Gr-1+ cells.7 Colonic M-MDSCs are described as CD11b+Ly6C+CD103+CX3CR1hi or CD11b+CD14+CX3CR1+ cells that produce high levels of IL-12, IL-23, inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF-α).8,9 MDSCs in the peripheral blood of patients with CAC have been described as Lin−/Colonic M-D103−CX3CR1int or CD11b+CD14+CX3CR1+ cells in humans has been extensively reported. New knowledge of both G-MDSCs and neutrophils provides an opportunity to distinguish these cell types (table 1).

Compared with neutrophils, G-MDSCs exhibit reduced expression of CD16 and CD62L, and increased expression of CD11b, CD66b, CD115, and CD244, and have increased reactive oxygen species (ROS) and arginase 1 (Arg-1) activity.19 Neutrophils have higher levels of lysosomal and proteasomal enzymes and stronger cytotoxicity, lytic activity and phagocytosis than G-MDSCs.20 Furthermore, neutrophils are on top of the erythrocyte fraction, and G-MDSCs are in the peripheral blood mononuclear cell fraction after density centrifugation.18 Finally, the nuclear morphology of neutrophils is hypersegmented, with more than four nuclear lobes (human) or a clover-leaf shape (mouse). G-MDSCs have a horseshoe-shaped or banded-shaped nucleus (human) or a ring-shaped nucleus (mice) (figure 1C).20

| Table 1 Differences between G-MDSCs and neutrophils |
|-----------------------------------------------|
| **Category**                   | **Neutrophils** | **G-MDSCs** | **Models** | **References** |
| Surface markers | Reduced CD115 and CD244. | Increased CD115 and CD244. | Mice | 113 |
| Density centrifugation | On top of the erythrocyte fraction. | In the PBMC fraction. | Human | 114 |
| Gene profiles | High granule proteins, NADPH complex subunits, peroxidases; high expression of genes associated with NF-κB signaling, TNF pathways, and lymphotxin-receptor signaling. | Upregulation of MPO, cell cycle and autophagosome proteins, G-protein signaling, the CREB pathway, Arg-1, iNOS, ROS, and IL-10. | Mice | 19 |
| Immunosuppression | Do not suppress T cells and promote IFN-γ production. | Inhibit antigen-specific T cell responses. | Human or mice | 113 |
| Lytic activity | Increased LAMP2 expression; highly active lysosomes and proteasomes. | Reduced LAMP2 expression. | Mice | 113 |
| Cytotoxicity | Kill tumor cells through ROS and RNS, activate T cells, and recruit M1 macrophages. | Not applicable. | Mice | 115 |
| Phagocytic activity | Increased. | Decreased. | Mice | 116 |
| Differentiation | Cannot be converted into G-MDSCs. | Differentiate into neutrophils under GM-CSF. | Mice | 116 |

CREB, cAMP-response element binding protein; Arg-1, arginase 1; GM-CSF, granulocyte-macrophage colony stimulating factor; G-MDSCs, granulocytic myeloid-derived suppressor cells; IFN-γ, interferon-γ; IL-10, interleukin 10; iNOS, inducible nitric oxide synthase; LAMP2, lysosomal-associated membrane protein 2; MPO, myeloperoxidase; NADPH, nicotinamide adenine dinucleotide phosphate; NF-κB, nuclear factor-κB; PBMC, peripheral blood mononuclear cell; RNS, reactive nitrogen species; ROS, reactive oxygen species; TNF, tumor necrosis factor.

**ROLE OF MDSCS/ILCS/THE GUT MICROBIOTA IN THE PATHOGENESIS OF IBD**

CAC was once thought to be a serious complication of IBD. IBD-related chronic non-resolving inflammation is a major driver of CAC. Acute intestinal inflammation is characterized by leukocyte influx followed by macrophage phagocytosis to clear injurious stimuli, leading to pathological regulation of CAC. The transition from G-MDSCs to neutrophils is halted in CAC, which results in the continuous accumulation and activation of G-MDSCs. It is difficult to distinguish G-MDSCs from neutrophils only by phenotypic differences, although the classification of G-MDSCs as CD11b+Ly6G+Ly6C+ cells in mice and HLA-DR+CD33+CD11b+CD15+ cells in humans has been extensively reported. New knowledge of both G-MDSCs and neutrophils provides an opportunity to distinguish these cell types (table 1).

Compared with neutrophils, G-MDSCs exhibit reduced expression of CD16 and CD62L, and increased expression of CD11b, CD66b, CD115, and CD244, and have increased reactive oxygen species (ROS) and arginase 1 (Arg-1) activity.19 Neutrophils have higher levels of lysosomal and proteasomal enzymes and stronger cytotoxicity, lytic activity and phagocytosis than G-MDSCs.20 Furthermore, neutrophils are on top of the erythrocyte fraction, and G-MDSCs are in the peripheral blood mononuclear cell fraction after density centrifugation.18 Finally, the nuclear morphology of neutrophils is hypersegmented, with more than four nuclear lobes (human) or a clover-leaf shape (mouse). G-MDSCs have a horseshoe-shaped or banded-shaped nucleus (human) or a ring-shaped nucleus (mice) (figure 1C).20

**Identification of G-MDSCs versus neutrophils**

G-MDSCs are pathologically activated and relatively immature neutrophils that have been implicated in the pathological regulation of CAC. The transition from G-MDSCs to neutrophils is halted in CAC, which results in the continuous accumulation and activation of G-MDSCs. It is difficult to distinguish G-MDSCs from neutrophils only by phenotypic differences, although the classification of G-MDSCs as CD11b+Ly6G+Ly6C+ cells in mice and HLA-DR+CD33+CD11b+CD15+ cells in humans has been extensively reported. New knowledge of both G-MDSCs and neutrophils provides an opportunity to distinguish these cell types (table 1).
resolution and tissue homeostasis. In patients with IBD, although innate immune-mediated responses to bacteria resolve within days, these stimuli activate the adaptive immune response and trigger a second wave of leukocyte influx into tissues. MDSCs are an important component of these cells and play a pivotal role in the pathogenesis of IBD by secreting proinflammatory cytokines, as well as interacting with the host immune system and the gut microbiota.

**Role of MDSCs in the pathogenesis of IBD**

MDSCs were once regarded as endogenous antagonists of immune system functionality in mucosal inflammation due to their immunosuppressive effects on effector T cells. MDSCs are recruited and activated in intestinal tissue when challenged with inflammation. However, colonic MDSCs fail to inhibit the inflammatory response and instead promote effector T cell expansion. IEC-derived and activated immune cell-derived cytokines and gut microbiota-derived factors lead to the recruitment and activation of MDSCs in the intestine (figure 2). In chronic colitis mice, colonic G-MDSCs acquire stimulatory antigen-presenting functions and induce T cell activation and IL-17 production. Adoptively transferred CD11b+Ly6C hi cells are converted into proinflammatory cells and promote intestinal inflammation. Human HLA-DR−/loCD33+CD15+CD14+ MDSCs from the peripheral blood of patients with IBD not only fail to suppress the autologous T cell response but also enhance T cell proliferation. Furthermore, activated MDSCs inhibit the antigen uptake and processing by DCs and subsequent CD4+ T cell proliferation and activation, which leads to inadequate clearance of pathogenic bacteria at sites of bacterial penetration, resulting in a sustained inflammatory stimulus (figure 2). MDSC-derived ROS are the major inducers of the IEC damage, but
MDSC-derived transforming growth factor-β (TGF-β) promotes IEC repair. These double effects drive chronic inflammation. Under the colonic inflammatory milieu, MDSCs downregulate the expression of CCAAT/enhancer-binding protein beta (CEBPβ), a critical transcription factor associated with the suppressive function of MDSCs, and secreted increased levels of proinflammatory molecules. In addition, MDSC-derived proinflammatory molecules, such as IL-6, TNF-α, granulocyte-macrophage colony stimulating factor (GM-CSF) and C-X-C motif chemokine ligand 1 (CXCL1), promote Th17 cell differentiation and the influx of macrophages and neutrophils, resulting in a strong inflammatory response (figure 2). Therefore, MDSCs are the key factors in the continual reinitialization of chronic intestinal inflammation over long periods of time and the targetable link between acute inflammation and chronic inflammation in IBD.

Role of ILCs in the pathogenesis of IBD

Susceptibility loci for IBD are closely linked to ILC function and the depletion of ILCs reduces the severity of colonic inflammation. ILC1s and ILC3s are enriched in the intestinal tissue of patients with CD and promote intestinal inflammation by producing interferon-γ (IFN-γ) and IL-17. Fontolizumab and secukinumab, two humanized neutralizing monoclonal antibodies (mAbs) against IFN-γ and IL-17, respectively, can effectively inhibit CD activity. ILCs isolated from patients with active CD showed increased gene expression of IL-23R, which is a key ILC3 cytokine receptor. IL-23 regulates the selective accumulation of the ILC3 population, which is characterized by inflammatory cytokine expression and is associated with intestinal inflammation in CD. IL-23 produced by MDSCs is a driver of inflammation and tumors. Thus, IL-23 from MDSCs may promote the expansion of ILC3s through IL-23R and is expected to be a target for the treatment of IBD and CAC.
Intestinal ILC2s induced strong type 2 innate inflammation by secreting cytokines, such as IL-4, IL-5, and IL-13. Previous studies showed that ILC2-derived IL-4, IL-5, and IL-13 were linked to impaired epithelial barrier function in the gut and drove UC. G-MDSCs effectively suppressed the cytokine production of ILC2s in allergy-induced airway inflammation models, thereby alleviating airway inflammation, although the potential relationship between ILC2s and MDSCs in IBD remains largely unknown. Interestingly, ILC2s could prevent acute gastrointestinal graft-versus-host disease following hematopoietic stem cell transplantation, which was associated with ILC2-derived IL-13 promotion of MDSCs and reductions in proinflammatory Th1 and Th17 cells. In the context of acute promyelocytic leukemia, activated ILC2s promoted MDSC activation through IL-13 secretion and were associated with poor tumor control. Thus, ILC2s may limit antitumor immune responses indirectly by modulating MDSC functions. However, ILC-derived IL-22 and amphiregulin play protective roles in BD by promoting mucus secretion and epithelial cell repair. Thus, the crosstalk between MDSCs and ILCs plays an important and complex role in the pathogenesis of IBD. There are more regulatory mechanisms of MDSCs in the pathogenesis of CAC than those of ILCs, although additional regulatory effects of ILCs in cancer are being discovered. Investigating the relationship between ILCs and MDSCs will help clarify the regulatory mechanism of ILCs and MDSCs in IBD, which could provide therapeutic benefit in the treatment of IBD and CAC.

Role of the microbiota in the pathogenesis of IBD

There are already abundant data confirming the importance of the gut microbiota in the pathogenesis of IBD and CAC by inducing host immune response disturbance and chronic inflammation. Some pathogenic microbiota, such as Mycobacterium avium subspecies paratuberculosis, Cytomegalovirus, and adherent-invasive Escherichia coli, participate directly in the pathogenesis of IBD. Furthermore, reduced microbial diversity is an important reason for IBD. The loss of Bacteroides suppresses the conversion of nondigestible dietary fiber into short-chain fatty acids. A reduction in Clostridium enhances mucosal permeability, which results in the exposure of antigens and bacterial Toll-like receptor ligands, thereby activating pathogenic immune responses.
Table 2  Possible therapy strategies for CAC based on MDSC regulation

| Strategies                          | Events                                      | Subsets | Models                                      | References |
|-------------------------------------|---------------------------------------------|---------|---------------------------------------------|------------|
| Gemcitabine                         | Reduce intratumoral MDSCs.                  | MDSCs   | mHer2/CT-26-bearing mice                    | 92         |
| Oxaliplatin and IL-12               | Reduce intratumoral MDSCs.                  | MDSCs   | MC-38 liver metastasis model               | 93         |
| 5-FU, oxaliplatin, and bevacizumab  | Decrease G-MDSCs in the peripheral blood.   | G-MDSCs | Patients with mCRC                          | 94         |
| 5-FU, folinic acid, bevacizumab, and anakinra | Decrease M-MDSCs in the peripheral blood.   | M-MDSCs | Patients with mCRC                          | 95         |
| 5-FC and Toca 511                   | Decrease MDSCs in both the liver and brain. | MDSCs   | CT-26 liver and brain metastasis model      | 96         |
| Anti-SEMA4D Ab (VX15/2503)          | Inhibit MDSC expansion.                     | MDSCs   | Patients with mCRC                          | 101        |
| Anti-cKit Ab                        | Prevent MDSC accumulation through blocking cKit-SCF interactions. | MDSCs   | MCA-26-bearing mice                         | 102        |
| Anti-CCR2 Ab                        | Block radiation-induced MDSC infiltration. | M-MDSCs | MC-38-bearing mice                          | 103        |
| OX40 agonist                        | Reduce intratumoral MDSCs.                  | MDSCs   | CT-26-bearing mice                          | 104        |
| Pembrolizumab                       | --                                          | --      | Patients with MSI-H CRC                     | 105        |
| Nivolumab                           | --                                          | --      | Patients with MSI-H CRC                     | 106        |
| Radiation                           | Reduce intratumoral MDSCs.                  | MDSCs   | CT-26 and MC-38-bearing mice                | 117        |
| Nitroaspirin                        | Decrease the recruitment or survival of intratumoral MDSCs, and Arg-1, NOS2, PNT expression. | MDSCs   | CT-26-bearing mice                          | 118        |
| PDE-5 inhibitors (sildenafil and tadalafil) | Decrease the recruitment of intratumoral MDSCs and Arg-1, NOS2 expression. | G-MDSCs | CAC mice                                    | 107        |
| Triterpenoids                       | Inhibit ROS expression.                     | MDSCs   | MC-38-bearing mice                          | 108        |
| Etopoxir                            | Block the immunosuppressive functions of MDSCs. | MDSCs   | MC-38-bearing mice                          | 109        |
| GSK872                              | Reduce circulating MDSCs by inhibiting RIPK3 signaling. | MDSCs   | APC<sup>min</sup>/<sup>+</sup> mice, MC-38-bearing mice | 110        |
| Metformin                           | Inhibit the immunosuppressive functions of G-MDSCs by reducing p-STAT3 levels. | G-MDSCs | CT-26-bearing mice                          | 111        |
| Fluconazole                         | Decrease MDSC accumulation.                 | MDSCs   | CAC mice                                    | 50         |
| TFF2                                | Arrest MDSC proliferation.                  | MDSCs   | CAC mice                                    | 22         |
| EZH2 inhibitor                      | Promote MDSC generation from progenitor cells during IBD. | MDSCs   | CAC mice                                    | 89         |
| Juglone                             | Decrease MDSC accumulation.                 | MDSCs   | CT-26-bearing mice                          | 112        |
| Hyperoxia                           | Suppress G-MDSC-derived exosome production. | G-MDSCs | CAC mice                                    | 12         |

Ab, antibody; Arg-1, arginase 1; CAC, colitis-associated cancer; CCR2, chemokine (C-C motif) receptor 2; c-Kit, cellular kit proto-oncogene; EZH2, enhancer of zeste homolog 2; 5-FC, 5-fluorocytosine; 5-FU, 5-fluorouracil; G-MDSCs, granulocytic MDSCs; IBD, inflammatory bowel disease; IL, interleukin; mCRC, metastatic colorectal cancer; MDSCs, myeloid-derived suppressor cells; M-MDSCs, monocytic MDSCs; MSI-H, microsatellite instability-high; DX40, oxford 40; PDE-5, phosphodiesterase 5; PNT, peroxynitrite; RIPK3, receptor interacting protein kinase 3; ROS, reactive oxygen species; SEMA4D, semaphorin 4D; STAT3, signal transducer and activator of transcription 3; TFF2, trefoil factor 2.

responses. Fecal microbiota transplantation can increase fecal microbial diversity in patients with active UC and is a promising treatment to induce remission. Interestingly, IBD-associated microbiota can induce the accumulation and proinflammatory functions of MDSCs. The combined action of enterotoxigenic Bacteroides fragilis and IL-17 on IECs promoted the differentiation of proinflammatory M-MDSCs. This may explain why bone marrow-MDSCs potently suppress CD4<sup>+</sup> T cell responses but fail to control colitis-associated immune responses in vivo. Bone marrow cells incubated with Candida tropicalis exhibited MDSCs features. Mice deficient in fungal killing exhibit dysbiosis and have increased susceptibility to colitis and CAC. The role of the gut microbiota in shaping MDSC phenotype and function remains to be further studied. The important task is to identify the unique microbiota that drives IBD and the relationship of the gut microbiota with myeloid cells, which could help in the development of personalized intervention...
strategies that correct abnormalities and induce sustainable treatment responses in patients with IBD.

EFFECT OF MDSCS ON IECs DURING THE DEVELOPMENT OF CAC

Dysplasia has been linked to CAC initiation, in which disease promotion is driven by the sustained proliferation of IECs and genomic alterations in IECs. MDSCs are already the targetable link between IBD and CAC. Here, we review the current knowledge concerning how MDSCs participate in the CAC initiation by mediating proliferation signals and DNA damage in IECs (figure 3).

Under normal conditions, signal transducer and activator of transcription 3 (STAT3) plays an important role in maintaining intestinal epithelial homeostasis by promoting IEC proliferation. Under IBD conditions, MDSC-derived IL-6 promotes the continuous activation of STAT3 through the IL-6R signaling pathway, which results in uncontrollable IEC proliferation.51 Additionally, IL-6-activated STAT3 promotes the secretion of sphingosine 1-phosphate (SIP), which binds SIP receptor 1 and plays a critical role in IEC dysplasia by inhibiting p53 expression.52 Receptor of advanced glycation end products (RAGE) initiates cellular activation of multiple pathways and is multifunctional in the carcinogenesis of various solid tumors.53 Extracellular S100A8/9 derived from MDSCs activates β-catenin via RAGE, which initiates dysplasia in IECs.54 Interestingly, the activation of the RAGE signaling pathway also promotes IL-6 production, which contributes to STAT3 activation and p53 expression inhibition.55 Therefore, MDSC-derived S100A8/9 plays an important role in dysplasia and CAC initiation. TNF-α is a major cytokine that mediates MDSC functions in IBD. The loss of tumor necrosis factor receptor (TNFR) in IECs blunts Wnt signaling and wound healing in IBD mice, indicating an integral role of TNF-α in mucosal regeneration.56 TNF-α activates β-catenin via protein kinase B and induces Wnt expression in crypt base stem cells.57 Additionally, TNF-α drives IEC apoptosis during colitis, which in turn accelerates the proliferation of IECs.58 IL-10 and TGF-β, the key molecules that mediate MDSC immunosuppression during colitis, promote IEC proliferation by activating Wnt signaling and promoting c-Myc expression in IECs.59 Chronic exposure to ROS promotes cell canceration by promoting DNA damage and chromosomal instability (CIN) in IECs. Increased oxidative stress leads to p53 mutations, which initiate dysplasia in IECs. Genetic and epigenetic changes in DNA further contribute to carcinoma at the later stage of atypical hyperplasia. During IBD, excessive MDSC-derived ROS may promote the transition from chronic inflammation to dysplasia by damaging IEC DNA.60 The levels of cyclo-oxygenase-2 (COX-2) and COX-2-derived prostaglandin E2 (PGE2) are significantly elevated in patients with IBD.61 MDSCs in preneoplastic colon adenomas commonly express COX-2 and PGE2. PGE2 initiates CIN in IECs, enhances the stemness of tumor cells, transforms IECs into cancer-initiating cells, and drives CAC.62 Thus, MDSCs may promote CAC through COX-2 and PGE2.

MDSC-related oxidative stress, aberrant inflammation, and tissue repair signaling lead to the activation of p53 mutations and Wnt/β-catenin, which initiate dysplasia in IECs. MDSCs also contribute to CAC at the later stage of IBD by promoting genetic and epigenetic changes in DNA.

ROLE OF MDSCS IN CAC PROGRESSION

It is well known that MDSCs promote CAC through immune suppression. However, the rescue of antitumor immunity is insufficient to achieve the expected clinical effect, although the results of animal experiments showed that targeting MDSCs is an emerging opportunity for enhancing the effectiveness of anti-CAC therapy. Researchers have found that MDSCs also promote CAC progression through a non-immunosuppressive effect.

Immunosuppression

Under CAC conditions, stromal cell-derived and tumor-derived factors mobilize myeloid progenitors to develop the phenotypic features of MDSCs and acquire suppressive activity toward immune cells through multiple mechanisms. CD8+ cytotoxic T lymphocytes (CTLs) are central players in controlling cancer.63 MDSCs predominantly suppress CTLs via effector molecules such as Arg-1, ROS, and nitric oxide (NO). Peroxynitrite formed by the cooperative activity of ROS and NO leads to the nitration of tyrosines in the T cell receptor (TCR)-CD8 complex, which disrupts the conformational flexibility of the TCR-CD8 complex. The damaged TCR-CD8 complex cannot interact with peptide-loaded major histocompatibility complex I (MHC-I), which results in the unresponsiveness of CD8+ T cells to antigen-specific stimulation.64 65 MDSCs directly cleave CD62L on the surface of naive T cells by expressing A disintegrin and metalloproteinase domain 17 (ADAM17), which suppresses naive T cell differentiation into CTLs (figure 4).66 MDSCs also induce regulatory T cell (Treg) expansion by producing TGF-β.67 Tumor-infiltrating MDSCs are exposed to the hypoxic microenvironment, which results in an increase in hypoxia-inducible factor 1α (HIF-1α).12 HIF-1α promotes the induction of Arg-1 and iNOS and the upregulation of inhibitory V-domain Ig suppressor of T cell activation and PD-L1, which promoted MDSC-mediated T cell suppression.68 69 The hypoxic microenvironment causes the activation of CD45 protein tyrosine phosphatases, which results in the downregulation of STAT3 activity and promotes M-MDSC differentiation to tumor-associated macrophages.70 These alterations result in the potent non-specific immunosuppressive activity of MDSCs within the tumor.

Non-immunosuppression

MDSCs have been shown to play pivotal and intricate roles in promoting CAC metastasis. Great efforts focusing on the regulatory network of MDSCs in CAC have been made. We will discuss some new advances in the field,
documenting an increase in the sphere of influence of MDSCs (figure 4).

Epithelial-mesenchymal transition (EMT) plays pivotal roles in CAC metastasis. The TGF-β/Smad signaling pathway is an essential driver of EMT. In a model of uveal melanoma, G-MDSCs are recruited to primary tumors by CXCL5 and then induce EMT by the TGF-β, epidermal growth factor, and hepatocyte growth factor signaling pathways, which promote cancer cell dissemination. MDSC-derived matrix metalloproteinase 9 (MMP9) increases the bioavailability of vascular endothelial growth factor and promotes angiogenesis, which was crucial in CAC metastasis. The promotion of tumor metastasis by forming a premetastatic niche (PMN) is widely accepted. In CRC liver metastasis mice, MDSCs promote liver-specific metastasis by promoting PMN formation.

In other tumor models, MDSC-derived premetastatic proteins such as Bv8, MMP9, S100A8/9, TGF-β, and inhibitory molecules participate in multiple stages of PMN formation and evolution by increasing vascular permeability and the degradation of tight junction proteins, suppressing the immune response, and promoting the formation of an inflammatory microenvironment. Our previous research showed that G-MDSCs promoted CAC cell stemness through exosomal S100A9.

TARGETING MDSCS FOR CAC THERAPY

The multifunctional features of MDSCs in IBD/CAC force us to comprehensively assess the role of MDSCs in the prevention and treatment of CAC. Here, we summarize the microenvironmental characteristics of CAC, the role of MDSCs in the response to anti-inflammatory IBD treatment, and the possible approaches targeting MDSCs for CAC therapy.

Microenvironmental characteristics of CAC

CAC and sporadic colorectal cancer (sCRC) are the two major forms of CRC. Chronic inflammation and immune dysregulation predispose IECs to dysplasia and eventually lead to the development of CAC in patients with IBD, whereas the accumulation of mutations in oncogenes and tumor suppressor genes drives the initiation of sCRC. The unique initiation mechanisms lead to the unique and complex microenvironment of CAC. First, sustained chronic inflammation leads to DNA damage that exceeds the capacity of DNA repair, which is the major mechanism responsible for the microsatellite instability (MSI) phenotype. MSI is more likely to occur in patients with CAC than in patients with sCRC (approximately 50% compared with 15%). The microenvironment of MSI CAC contains strong Th1 and CTL components. The increased number of tumor ‘neoantigens’ created by the chronic inflammation-driven high mutational load may be an important factor. Multiple immune checkpoints, such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-L1, are highly elevated in MSI CRC relative to microsatellite stability (MSS) CRC. Additionally, chronic inflammation damages epithelial integrity and increases intestinal permeability in patients with CAC, which allows luminal microbiota to freely enter the lamina propria (LP) and promote tumor progression.

Role of MDSCs in the response to anti-inflammatory IBD treatment

Persistent chronic inflammation plays an important role in the initiation of CAC. Anti-inflammatory treatment is an important means to prevent the development of CAC. In experimental mouse models, a variety of anti-inflammatory agents, such as zileuton, infliximab, and omeprazole, have been suggested to prevent the occurrence of CAC. Earlier and intensive anti-inflammatory therapy should be considered for either mitigating clinical courses or preventing the development of CAC in high-risk patients with IBD.

Relapse and intolerance to existing drugs, such as anti-biotics, corticosteroids, and aminosalicylate, always occur during the treatment of IBD. Enormous efforts have been made to develop new treatment strategies based on immunosuppressive interventions. MDSCs are one cell type with a well-recognized role in limiting immune reactions and play an important role in the response to IBD treatment. Dexamethasone suppresses HIF-1α-dependent glycolysis in MDSCs through glucocorticoid receptor signaling and thus promotes the immunosuppressive activity of MDSCs. INK128, an mTOR kinase inhibitor, is in clinical development. In dextran sodium sulfate (DSS)-induced murine colitis, INK128 can maintain the immature state of MDSCs by elevating S100A8/9 expression and reducing the production of inflammatory cytokines. Glatiramer acetate enhances IL-10 and TGF-β secretion while reducing IL-23 and IL-6 secretion from MDSCs via the recognition of paired Ig-like receptor B, thus favoring conditions that suppress Th17 maturation but enhance Treg induction. Atorvastatin promotes the expansion of G-MDSCs, which suppress T cell responses via NO production. Transfer of these G-MDSCs attenuates chronic colitis. In an IBD model induced by the bacterium Helicobacter hepaticus, oral administration of diallyl trisulfide reduces colon inflammation by limiting the recruitment of G-MDSCs in the colon. GSK343, an inhibitor of enhancer of zeste homolog 2 (EZH2), shows beneficial effects on DSS-induced colitis by increasing the number of MDSCs in the LP. Therefore, the immuno-suppressive effect of MDSCs plays an important role in limiting IBD-related inflammation and may be used as an indicator to assess the response to IBD therapeutic strategies.

Indeed, in addition to chronic inflammation, the initiation of CAC is also related to cumulative genetic changes, abnormal immune regulation, and intestinal microfloral imbalance. Anti-inflammatory preparations-mediated MDSC expansion is also likely to shape CAC. MDSC-derived ROS participate in CAC initiation by mediating proliferation signals and DNA damage in IECs, which
promotes the transition from inflammation to dysplasia. MDSC-derived S100A8/9 activated β-catenin via RAGE, which initiates dysplasia in IECs. Furthermore, MDSCs suppress the body's immune response, which is beneficial for abnormally hyperplastic IECs to escape immune surveillance. MDSC-mediated chronic inflammation and an immunosuppressive microenvironment are suitable for the settlement and survival of tumor cells. Persistent application of antibiotics and glucocorticoid drugs leads to imbalance in the gut microbiota, which is a key event leading to chronic tissue injury and CAC initiation. Therefore, anti-inflammatory treatment is expected to become a specific preventive measure for CAC. However, developing true anti-inflammatory treatments to prevent CAC remains inherently challenging due to anti-inflammatory-related side effects and potential risks.

**Role of chemotherapy drugs in MDSC depletion**

The majority of chemotherapy drugs have been shown to reduce the tumor infiltration of MDSC (table 2). Sunitinib potently decreased MDSC accumulation and rescued T cell inhibition in colon cancer cell-bearing mice. MDSCs are the major components of the tumor microenvironment in both murine models of patients with colon cancer and CRC, although the microenvironments are different. Sunitinib-mediated MDSC elimination is beneficial in restoring antitumor immunity in patients with CAC. However, sunitinib malate combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) chemotherapy did not significantly improve progression-free survival in patients with metastatic colorectal cancer (mCRC) compared with that of FOLFIRI alone. The sensitivity of CRC cells themselves may be the main reason for the failure of sunitinib in clinical trials. Additionally, in patients with CAC, the microenvironment in which MDSCs exist is more complex due to the microbiota, dietary components and metabolites. In colon cancer cell-bearing mice, both gemcitabine and oxaliplatin induced protective antitumor immunity by eliminating MDSCs. 5-Fluorouracil (5-FU) has a good effect on MDSC depletion. Bevacizumab in combination with 5-fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or leucovorin calcium/5-fluorouracil (LV5FU2) and anakinra could decrease the number of G-MDCs or M-MDCs in patients with mCRC. In CT-26 metastatic mice, 5-fluorocytosine in combination with Toca 511 significantly decreased the number of MDSC in both the liver and brain in mCRC mice. A phase I study of Toca 511 and Toca FC in solid tumors, including mCRC, has been completed and showed a promising novel treatment strategy. Gemcitabine and 5-FU activate the pyrin domain containing-3 protein (NLRP3)-dependent caspase-1 activation complex in MDSCs, resulting in the production of IL-1β, which limits the antitumor efficacy. Gemcitabine and 5-FU exert an improved antitumor effect when combined with an IL-1 receptor antagonist. In murine mammary cancer models, anthracyclines not only eliminated peripheral and intratumoral MDSCs but also caused a shift toward a more differentiated phenotype featuring upregulated Gr-1 and downregulated CD11b in MDSCs. Thus, anthracycline may have synergistic effects with other anti-CAC agents by effectively depleting MDSCs, which provides a promising strategy for potential CAC therapy.

**Role of antibodies in MDSC inhibition**

Antibodies have been found to block the expansion of MDSCs in CRC (table 2). Preclinical studies demonstrated that blocking semaphorin 4D (SEMA4D) inhibited MDSC expansion in patients with CRC. Phase I clinical studies of anti-SEMA4D mAb (VX15/2503) in mCRC are underway (NCT03373188). In MCA-26-bearing mice, blocking the stem cell factor (SCF) receptor–SCF interaction by anti-cKit (anti-cellular kit proto-oncogene) mAbs significantly reduced MDSC expansion and restored the proliferative responses of tumor-infiltrating T cells. An anti-chemokine (C-C motif) receptor 2 (CCR2) antibody blocked radiation-induced M-MDCs infiltration. In CT-26-bearing mice, the oxford 40 (OX40) agonist antibody significantly decreased the expression of TGF-β in MDSCs.

MSI is a main type of genomic instability factor. Carcinogenesis and malignant potential in CAC are closely associated with MSI caused by TGFβRII mutations and hMLH1 hypermethylation. Chronic inflammation and folate deficiency lead to high frequencies of MSI in patients with IBD and CAC. Brentnall et al detected MSI in 46% of high-grade dysplasias, in 40% of carcinomas, and in 50% of non-neoplastic mucosa. Ishitsuka et al found MSI in 8% of dysplasias, in 50% of carcinomas, and in 9% of non-neoplastic mucosa from patients with UC who had long durations of neoplasms. Schulmann et al detected MSI in 67% of high-grade dysplasias and in 67% of carcinomas. Therefore, approximately half of the CAC cases are MSI-H. MSI-H is detected in only approximately 15% of sCRC cases. MSI-H tumors selectively upregulate the production of various immune checkpoint factors, such as PD-1, PD-L1, and CTLA-4. Humanized anti-PD-1/PD-L1 mAbs have shown promising results in patients with CRC, and the clinical efficacy is especially significant in MSI CRC. Therefore, CAC is more likely to respond effectively to immunotherapy than sCRC, although this has not been analyzed separately. PD-1/PD-L1 mAbs are another available drug for CAC immunotherapy, although the exact clinical efficacy needs to be further defined. It is worth noting that non-neoplastic mucosa and high grade-dysplasia in CAC have also been found to have MSI. Early application of anti-PD-1/PD-L1 mAbs may be beneficial for either mitigating clinical courses or preventing the ultimate development of CAC in high-risk patients with IBD.

**Role of small molecule inhibitors in MDSC inhibition**

The alternative strategy to suppress MDSCs is to inhibit their effector molecules and catabolic enzymes (table 2). In CAC mice, Arg-1 and iNOS can be blocked by nitroaspirin and phosphodiesterase-5 inhibitors. In MC-38-bearing mice, both tryptophan and etomoxir dampened the immunosuppressive effects of MDSCs by reducing ROS secretion. In Apcmin/+ mice and MC-38-bearing mice, GSK872 inhibited
MDSC to produce IL-23, IL-1β, and COX-2, which inhibited tumor growth. Metformin downregulated the inhibitory functions of G-MDSCs by reducing STAT3 phosphorylation levels in MC-38-bearing mice. In addition, fluconazole, trefoil factor 2, and an EZH2 inhibitor have been found to suppress CAC susceptibility by decreasing MDSC accumulation. In CT-26-bearing mice, Juglone reduced the accumulation of MDSCs and impaired the immunosuppressive functions of MDSCs. In CAC mice, hyperoxia decreased G-MDSC exosome production by inhibiting HIF-1α-dependent Rab27a expression, which suppressed CAC susceptibility.

Overall, MDSC infiltration is a common feature in CAC models or patients. Various strategies targeting MDSCs may be beneficial in restoring antitumor immunity in CAC and are emerging opportunities for enhancing the effectiveness of anti-CAC therapy. It is noteworthy that the experimental conditions are different in colon cancer cell-bearing mice, chemically induced CAC mice, and patients with CAC and sCRC. The characteristics of MDSCs in each organ could be different. In the bone marrow (BM) and spleen, the major role of MDSCs is immune suppression. These cells may play a protective role in IBD. MDSCs existing underneath the intestinal mucosal surface have multiple functions due to the complex intestinal microenvironment. There are close and complex relationships between MDSC characteristics and the microbiota and dietary components. Research in this area is essential for the precise treatment of CAC, and the exact effect of these factors on CAC treatments based on MDSCs remains to be further studied.

CONCLUSION
MDSCs play multiple roles in CAC initiation and progression. Cumulative evidence demonstrates that targeting MDSCs is essential for immune system reactivation in CAC. Finding combination methods to eliminate MDSCs to achieve long-lasting clinical responses will be another critical issue and will be explored in future clinical trials. Due to the difficulty in manipulating human MDSCs, many of the published studies on CAC-infiltrating MDSCs have been done in mice. More studies in this area should focus on human-related content. The armamentarium for MDSC inhibition is expanding, and therefore the need to choose reasonable personalized medicine decisions will become increasingly important in the near future.

Contributors YW, YaD, and YZ contributed to the conception, content and writing. SW, YW, and YD contributed to the revisions. All authors read and approved the final manuscript.

Funding This work was supported by the National Science Foundation of China (81902906), Research Project of Jiangsu Commission of Health (K2019019), Jiangsu Province’s Key Medical Talents Program (ZDRC2016018), Jiangsu Province’s Medical Scientific Research Project (H2019102), Excellent Research Talents Cultivation Fund Program of The First People’s Hospital of Yancheng City (QN2018001), and Yancheng City’s Medical Science and Technology Program (YK2018004).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Shenjun Wang http://orcid.org/0000-0001-6584-1183

REFERENCES
1. Low D, Mino-Kenudson M, Mizoguchi E. Recent advancement in understanding colitis-associated tumorigenesis. Inflamm Bowel Dis 2014;20:2115–23.
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–35.
3. Segal AW. Studies on patients infected by the disease as a manifestation of impaired innate immunity. J Intern Med 2019;286:373–88.
4. Haile LA, von Wasielewski R, Gamrekelashvili J, et al. Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease: a New Immunoregulatory Pathway. Gastroenterology 2008;135:871–81.
5. Salminen A, Kaarniranta K, Kauppinen A. The role of myeloid-derived suppressor cells (MDSC) in the inflammmation process. Ageing Res Rev 2018;48:1–10.
6. Elliott LA, Doherty GA, Sheahan K, et al. Human tumor-infiltrating myeloid cells: phenotypic and functional diversity. Front Immunol 2017;8:86.
7. Ostanin DV, Kurmavea E, Furr K, et al. Acquisition of antigen-presenting functions by neutrophils isolated from mice with chronic colitis. JCI 2012;118:1490–1492.
8. Rivollier A, He J, Kole A, et al. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med 2012;209:138–55.
9. Vanoli C, Vallon-Eberhard A, Elinav E, et al. Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 2009;31:502–12.
10. Lin Q, Ren L, Jian M, et al. The mechanism of the premetastatic niche facilitating colorectal cancer liver metastasis generated from myeloid-derived suppressor cells induced by the S1PR1–STAT3 signaling pathway. Cell Death Dis 2019;10:693.
11. Wu L, Liu H, Guo H, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients. Oncol Lett 2018;15:9507–15.
12. Wang Y, Yin K, Tian J, et al. Granulocytic Myeloid-Derived Suppressor Cells Promote the Stenosis of Colorectal Cancer Cells through Exosomal S100A9. Adv. Sci. 2019;6:1901278.
13. Bronte V, Brandau S, Chen S-H, et al. Recommendations for myeloid-derived suppressor cell Nomenclature and characterization standards. Nat Commun 2017;8:12151.
14. Dumitru CA, Moses K, Trellakis S, et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 2012;61:1155–67.
15. Huang Y-K, Wang M, Sun Y, et al. Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry. Nat Commun 2019;10:3928.
16. Radhakrishnan J, Blechman G, Shrader C, et al. Colonic strictures following successful medical management of necrotizing enterocolitis: a prospective study evaluating early gastrointestinal contrast studies. J Pediatr Surg 1991;26:1043–6.
17. Cassetta L, Baekkevold ES, Brandau S, et al. Deciphering myeloid-suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother 2019;68:687–97.
18. Haile LA, Gamrekelashvili J, Manns MP, et al. CD49D is a new marker for distinct myeloid-suppressor cell subpopulations in mice. JCI 2010;120:203–10.
19. Rodríguez PC, Ernstoff MS, Hernandez C, et al. Arginase-I-Producing myeloid-suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553–60.
20. Pallay J, Tak T, Kamp VM, et al. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell. Mol. Life Sci. 2013;70:3813–27.
Semin patients with inflammatory bowel disease before and after infliximab paratuber splenic TFF2 to arrest myeloid cell expansion and cancer. 

Am J Gastroenterol

Matsuoka K, Iwao Y

Autoimmunity

Neut C, Bulois P

the pathogenesis of inflammatory bowel diseases. 

J Intern Med

regeneration after injury through TGF β Ostanin DV

cells in the inflammatory bowel diseases. 

Inflamm Bowel Dis

Goldberg J, Reinisch W

to severe Crohn's disease: a phase 2, randomized, double-blind placebo study. 

Dig Dis Sci

Bruce DW

immunosuppressive efficacy of infliximab in active and inactive ulcerative colitis. 

Semin Cancer Biol

Kumar V, Cheng P, Condamine T, et al. Cd45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and 

J Immunother Cancer 2020;8:e000609. doi:10.1136/jitc-2020-000609
promotes tumor-associated macrophage differentiation. *Immunology* 2016;44:303–15.

71 Toh B, Wang X, Keeble J, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cell differential infiltration by the primary tumor. *PLoS Biol* 2011;9:e1001162.

72 Peinado H, Zhang H, Matei IR, et al. Pre-Metastatic niches: organ-specific homes for metastases. *Nat Rev Cancer* 2017;17:302–17.

73 Brentnall TA, Crispin DA, Bronner MP, et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. *Cancer Res* 1996;56:1237–40.

74 Jernvall P, Mäkinen MJ, Karttunen TJ, et al. Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. *EuJ Cancer* 1999;35:197–201.

75 Bubb VJ, Curtis LJ, Cunningham MJ, et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. *Oncogene* 1996;12:2641–9.

76 Ishitsuka T, Kashiwagi H, Konishi F. Microsatellite instability in imprinted and neoplastic epithelium in ulcerative colitis. *J Clin Pathol* 2001;54:520–2.

77 Schulmam K, Mori Y, Croog V, et al. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. *Gastroenterology* 2005;129:74–85.

78 Smolkin KC, et al. Tumor-Infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. *Cancer* 2001;91:2417–22.

79 Lloasa NJ, Cruise M, Trott J, et al. Microsatellite instability: a marker for microsatellite instability in colorectal carcinoma. *Oncogene* 2005;129:74–85.

80 Belyaev NN, Abdolla N, Perillyeva YY, et al. Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSC) and inhibits experimental tumor growth. *Cancer Immunol Immunother* 2018;67:101–11.

81 Yuan S-J, Xu Y-H, Wang C, et al. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemotherapy resistance in triple-negative breast cancer. *J Nanobiotechnol* 2019;17:110.

82 Leonard JE, Fisher TL, Winter LA, et al. Nonclinical safety evaluation of VX15/2503, a humanized IgG4 anti-SEMAD4 antibody. *Mol Cancer Ther* 2015;14:964–72.

83 Fu Y-P, Wang GJ, Yin Q, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. *Blood* 2008;111:219–28.

84 Liang H, Deng L, Hou Y, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. *Nat Commun* 2017;8:8.

85 Gough MJ, Ruby CE, Redmond WL, et al. Oxoagonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. *Cancer Res* 2008;68:5206–15.

86 Li DT, Uram JN, Yang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015;372:2509–20.

87 Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142); an open-label, multicentre, phase 2 study. *Lancet Oncol* 2017;18:1180–91.

88 Lin S, Wang J, Wang L, et al. Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSCs. *Am J Cancer Res* 2017;7:41–52.

89 Umaparaj S, Youn J-W, Welter H, et al. Anti-inflammation triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. *Clin Cancer Res* 2010;16:1812–23.

90 Hossain F, Al-Khami AA, Wyczewicka D, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells in advanced cancer patients. *Cancer Immunol Res* 2015;3:1236–47.

91 Jayakumar A, Bothwell ALM. RIPK3 deficiency blocks immunosuppressive function of MDSCs and improves immune response in cancer. *Am J Cancer Res* 2015;5:220.

92 Gounaris E, Heffernan MJ, Heffernan JR, et al. Zileuton, a 5-lipoxigenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation. *PLOS One* 2015;10:e0121402.

93 Kim YJ, Hong KS, Chung JW, et al. Prevention of colitis-associated carcinogenesis by infliximab. *Cancer Discov* 2015;5:1314–33.

94 Patiolla JM, Zhang Y, Li Q, et al. Anti-Carcinogenic properties of omeprozole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats. *Int J Oncol* 2012;40:170–7.

95 Lu Y, Liu H, Bi Y, et al. Glucocorticoid receptor promotes the function of myeloid-derived suppressor cells by suppressing HIF1α-dependent glycolysis. *Cell Mol Immunol* 2018;15:618–29.

96 Shi G, Li D, Ren J, et al. mTOR inhibitor INK128 attenuates dextran sulphate sodium (DSS) induced colitis by promotion of MDSCs on Treg cell expansion. *J Cell Physiol* 2019;234:1618–29.

97 van der Touw W, Kang K, Luan Y, et al. Glatiramer acetate enhances myeloid-derived suppressor cell function via recognition of paired Ig-like receptor B. *J Immunol* 2018;201:1727–34.

98 Lei A, Yang Q, Li X, et al. Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis. *Immunology* 2016;149:432–46.

99 De Cicco P, Sanders T, Cirino G, et al. Hydrogen Sulfide Reduces Myeloid-Derived Suppressor Cell-Mediated Inflammatory Response in a Model of Helicobacter hepatis-Induced Colitis. *Front Immunol* 2018;9:499.

100 Zhou J, Huang S, Wang Z, et al. Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation. *Nat Commun* 2019;10:2427.

101 Farsaci B, Higgins JP, Hodgkiss JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. *Int J Cancer* 2012;130:1948–59.

102 Starling N, Vázquez-Mazon F, Cunningham D, et al. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. *Ann Oncol* 2012;23:119–27.

103 Ko H-J, Kim Y-J, Kim Y-S, et al. A combination of chemoinmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. *Cancer Res* 2017;77:2774–86.

104 Gonzalez-Aparicio M, Alzugur P, Mauleon I, et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumors and eradicates metastatic colorectal cancer in mice. *Gut* 2011;60:341–50.

105 Limagne E, Euwrad R, Thibaudeau M, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-Bevacizumab drug treatment regimen. *Cancer Res* 2016;76:5241–52.

106 Isambert N, Hervieu A, Rébé C, et al. Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (RAFU): a single-arm phase 2 study. *Oncoimmunology* 2018;7:e1471439.

107 Yazig K, Rodríguez-Agüirre ME, Lopez Espinoza F, et al. A retroviral replicating vector encoding cytosine deaminase and 5-FC induces immune memory in metastatic colorectal cancer models. *Mel Tumors Oncolytics* 2018;9:28–36.

108 Philbrick BD, Adamson DC. Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. *Expert Opin Investig Drugs* 2019;28:207–16.

109 Bruchard M, Mignot G, Derangère V, et al. Chemotherapy-triggered cathepsin B release in myeloid-suppressor cells activates the NLRP3 inflammasome and promotes tumor growth. *Nat Med* 2013;19:57–64.

110 Wang Y, et al. Ablative tumor radiation eradication by guest. Protected by copyright.http://jitc.bmj.com/ J Immunother Cancer: first published as 10.1136/jitc-2020-000609 on 13 October 2020. Downloaded from